Tag Archives: Medecins Sans Frontieres

Findings indicate two newest TB drugs, bedaquiline and delamanid in combination safe, promising for patients with few options

By on .

A study following outcomes of 28 patients with drug-resistant tuberculosis in three countries with high burdens of the disease found what the researchers cite as strong evidence that a combination of the two newest TB drugs could be part of a safe and effective treatment regimen. The  drugs, bedaquiline — which was approved by the […]

It’s the treatment, stupid . . . We’re reading why medicine is the best medicine for infectious diseases

By on .

Why Africa’s HIV crisis continues . . . – This opinion piece by Washington Post columnist Michael Gerson is troubling both in its assumptions and its glaring omissions. As a key Bush Administration advocate for the U.S. President’s Emergency Plan for AIDS Relief, Gerson is familiar with the conditions and challenges that have fueled the […]

Secret trade negotiations have life-threatening side effects . . . We’re reading about the Trans-Pacific Partnership

By on .

Help us fix the TPP – Médecins Sans Frontières depends on access to affordable drugs to balance the odds against people in places where life-saving treatment is scarce. The international humanitarian organization, which has a record of recognizing and responding to health threats others have ignored, explains in a video here how the lengthy and […]

TB advocates call on organizations, leaders to work together, speed access to existing treatments for drug resistant tuberculosis

By on .

They would like an answer on March 24 When World TB Day next Tuesday commemorates the discovery in 1882 of the bacteria that causes the disease, announcements and op-ed pieces will note the progress that has been made since, and will certainly call for more. A group of 89 organizations that last week sent a […]

Global Health 2014: Top 10 stories in HIV, TB around the world

By on .

Ebola – Why is Ebola one of the top 10 stories in HIV and TB globally? Because the current crisis in West Africa echoes the history of those epidemics, highlights weaknesses that will continue to dog ongoing work to conquer those epidemics, and has once again shown that neglecting infectious disease anywhere poses a threat […]

Linezolid: Affordable generic access win highlights obstacles to life-saving treatment

By on .

With side effects that include stomach pain, vision problems, vomiting, diarrhea,  and anemia as well as pain, weakness, and numbness in hands and feet, linezolid is not something you would take if you had much choice. But for patients in Khayelishta, a township in South Africa’s Western Cape where rates of poverty, HIV and tuberculosis […]

Access to treatments for MDR TB, hepatitis C, other health threats set to expand with UNITAID grants targeting market barriers

By on .

The first new tuberculosis drug in more than 40 years, a treatment for hepatitis C currently priced in the United States at $84,000, and an early infant diagnostic test for HIV are among the breakthrough medicines and technologies the global health financing organization UNITAID is aiming to make available to people in low- and middle-income […]

HIV patients starting treatment with advanced illnesses highlight need to improve testing, care links, authors say

By on .

A letter in this month’s Clinical Infectious Diseases backs earlier findings that even as access to medicine for HIV has expanded and greatly increased the numbers of people receiving treatment for the virus, large numbers of patients still are starting treatment in advanced stages of illness that earlier treatment would have prevented. One result, the […]

Drug maker seeks approval for use against multidrug-resistant tuberculosis

By on .

Makers of an investigational tuberculosis drug that has been urged for “compassionate use” approval in South Africa have applied to the European Medicines Agency to market the medicine as part of a combination therapy for multidrug-resistant tuberculosis. “If approved, bedaquiline could be one of the first drugs with a new mechanism of action for tuberculosis […]